Vimarsana
Biggest News Aggregation in the World

Page 6 - Development Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Development Contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Development Contact Today - Breaking & Trending Today

EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting - Vimarsana News

EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting

Published: May 23, 2024

/PRNewswire/ -- EpicentRx, a clinical-stage biopharmaceutical company, announced that The American Society of Clinical Oncology (ASCO) has invited Dr. Anthony...

Source: prnewswire.com
Related Topics:
United StatesPrnewswire EpicentrxLucyb KennedyAnthonyp ConleySaar YanivAshley ThomazBusiness Development ContactAmerican Society Of Clinical OncologyMd Anderson Cancer CenterEpicentrx IncAmerican SocietyClinical OncologyCancer CenterSarcoma SpecialistOral Abstract SessionDevelopmental TherapeuticsDevelopment Contact
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market - Vimarsana News

Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

Published: May 22, 2024

Using their SPID®-Technology, Laxxon Medical has manufactured a 3D printed oral tablet combining a GLP-1 receptor agonist and a permeation enhancer intended to increase bioavailabilityLXM.2 is being developed

Source: finanznachrichten.de
Related Topics:
San DiegoUnited StatesAlexander RuckdaeschelHelmut KerschbaumerJessica MchargueFrances HoggardAchim SchneebergerBusiness DevelopmentBusiness Development ContactLaxxon MedicalScreen Printed Innovative DrugChief ScientificAdvanced Patented GenericsChief StrategyDevelopment ContactCommunications ManagerIhr Portfolio
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors - Vimarsana News

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

Published: January 8, 2024

HANGZHOU, China--(BUSINESS WIRE)--Jan 8, 2024--

Source: bdtonline.com
Related Topics:
Dan EramianDonald WyattYuhong XuBusiness Development ContactOpus Biotech CommunicationsField BiopharmaceuticalsMedia ContactDevelopment ContactBusiness WireNation World
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout - Vimarsana News

Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

Published: January 2, 2024

JIANGSU, China--(BUSINESS WIRE)--Jan 2, 2024--

Source: eagletribune.com
Related Topics:
United StatesDaniel EramianWilliam Dongfang ShiRoyj WuOpus Biotech CommunicationsCo LtdDrug AdministrationBusiness Development ContactBusiness DevelopmentJiangsu Atom BioscienceInvestigational New DrugAtom BiosciencesAtom BioscienceMedia ContactDevelopment ContactVice PresidentBusiness Wire
CopperCorp Resources Closes C$1.38 Million Private Placement - Vimarsana News

CopperCorp Resources Closes C$1.38 Million Private Placement

Published: December 22, 2023

Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.

Source: juniorminingnetwork.com
Related Topics:
British ColumbiaUnited KingdomNew South WalesUnited StatesStephen SwattonVenture ExchangeCorporate Development ContactCoppercorp Resources IncCompany Management DiscussionCompanya ShareCompany RazorbackBritish Columbia Newsfile CorpCorp ResourcesPrivate PlacementEach UnitEach WarrantMultilateral InstrumentMinority Security HoldersSpecial TransactionsUnited States Securities ActDevelopment ContactCanadian Securities Administrator SystemElectronic Document Analysis